Drug

Reboxetine

Regulatory activity · MHRA

Emerging researchLate-stage development

Also known as Reboxetina.

RxNorm60842 ChEMBLCHEMBL383921UNII947S0YZ36I

Research papers

Active clinical trials

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Reboxetine for Obstructive Sleep Apnoea After Upper Airway Surgery: a Randomised, Double-blind, Placebo-controlled Study

Clinical trial2025-07-01Primary completion · ClinicalTrials.gov

The Relation Between Attentional, Sensory and Emotional Dysregulation in Adults With Posttraumatic Stress Disorder: a Double-blind, Placebo-controlled Randomized Controlled Trial of the Combined Treatment With Reboxetine and Methylphenidate

Clinical trial2025-07-01Primary completion · ClinicalTrials.gov

Studying the Role of Brain Molecules for Decision Making

Clinical trial2021-12-13Completed · ClinicalTrials.gov

Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans

Clinical trial2020-06-01Completed · ClinicalTrials.gov

Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects

Clinical trial2020-05-01Completed · ClinicalTrials.gov

The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making

Clinical trial2020-02-13Completed · ClinicalTrials.gov

Pharmacovigilance in Gerontopsychiatric Patients

Clinical trial2017-06-28Terminated · ClinicalTrials.gov

Drug Safety Update: Reboxetine: benefit-risk balance reviewed

Regulatory2014-12-11MHRA

International Committee of Medical Journal Editors

Clinical trial2014-04-01Completed · ClinicalTrials.gov

Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

Clinical trial2011-12-01Primary completion · ClinicalTrials.gov

Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.

Clinical trial2011-08-01Completed · ClinicalTrials.gov

Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus.

Research2000-12-01The Journal of neuroscience : the official journal of the Society for Neuroscience

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Reboxetine

Aliases & brands

Reboxetina

RxNorm CUI

60842

ChEMBL ID

CHEMBL383921

UNII

947S0YZ36I

Regulatory jurisdictions

mhra

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities

MHRA

Total events

mhraMedicines and Healthcare products Regulatory Agency· 1 event

2014-12-11Safety communicationSafety

Drug Safety Update: Reboxetine: benefit-risk balance reviewed

Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

27 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2021

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 27

Phase 12Phase 210Phase 35Phase 44Phase N / A6

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Unknown statusPH IVFundació Sant Joan de Déun=2492011

Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial

Unknown statusPH IVHospital Universitari Vall d'Hebron Research Instituten=422011

Entwicklung Neuronaler Repräsentationen Nach Schlaganfall: Verbesserung Motorischer Leistungen Durch Transkranielle Gleichstromstimulation Und Noradrenerge Co-Stimulation

CompletedPH IVUniversitätsklinikum Hamburg-Eppendorfn=122010

Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study

Unknown statusPH IVGeha Mental Health Centern=602007

Pharmacovigilance in Gerontopsychiatric Patients

TerminatedPH IIIHannover Medical Schooln=4072017

Recent completions

Trials that read out recently, adding to the completed evidence base.

Studying the Role of Brain Molecules for Decision Making

CompletedN/AUniversity of Zurichn=1602021

Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans

CompletedN/AUniversity of Oxfordn=1072020

Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects

CompletedPH IUniversity Hospital Bispebjerg and Frederiksbergn=242020

The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making

CompletedN/AUniversity of Zurichn=1202020

International Committee of Medical Journal Editors

CompletedPH IIIGuiyang Medical Universityn=2032014

Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.

CompletedN/AHadassah Medical Organizationn=352011

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 2000 · 2,294 cites

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Bromodeoxyuridine

Frequently co-studied with Reboxetine in the research literature.

1 shared paper

Fluoxetine

Frequently co-studied with Reboxetine in the research literature.

1 shared paper

Tranylcypromine

Frequently co-studied with Reboxetine in the research literature.

1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials
Regulatory event sources are credited in the Regulatory Timeline above.